Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 OCT 12 ... the most notable early successes been trastuzumab in breast cancer and imatinib in chronic myelogenous leukemia. Recently, several important breakthroughs have occurred, including the identification ...
2009 SEP 21 ... observation to experimental proof, the link between telomere loss, human cell aging, and chronic disease and the key dynamic relationships between telomere biology and cancer. ... vaccine targeting telomerase (GRNVAC1), currently in a Phase II clinical trial in acute myelogenousleukemia. The company is also researching small molecule compounds that transiently ...
2009 NOV 2 ... and others 4. Biochips/Microarrays 5. Chromosome Analysis a. Chronic Myelogenous Leukemia (CML) b. Acute Myeloid Leukemia (AML) c. Acute Lymphoblastic Leukemia (ALL) d. Malignant ...
2009 SEP 21 ... drug dasatinib, which blocks its activity and is currently approved for treating chronic myelogenous leukemia (CML). The scientists say that the presence of the receptor - a protein called integrin ...
2009 NOV 16 ... "First-line-treatment for chronic myelogenous leukemia (CML) is imatinib, but some patients do not respond or develop resistance to the drug, ...
2009 NOV 9 ... stem cell transplantation (ASCT) is a potentially curative treatment for patients with chronic myelogenous leukemia (CML) and was previously considered the preferred treatment for newly diagnosed CML. The ...
2009 NOV 9 ... "were included if they had a first allogeneic or syngeneic HCT for acute leukemia, chronic myelogenous leukemia (CML) or myelodysplastic syndromes (MDS), or autologous HCT for acute myelogenous ...
2009 SEP 28 ... 24 patients who received allogeneic SCT from an HLA-matched sibling donor for acute and chronic myelogenous leukemia. Univariate analysis showed that two factors (the serum CsA level at the third week ...
2009 OCT 19 ... BMS-354825) is approved for use in imatinib (Gleevec; STI 571)resistant or-intolerant chronic myelogenous leukemia and may be useful for other tumors in the central nervous system (CNS)," scientists in ...
2009 SEP 28 ... with a peptide/MHC tetramer library. Patients with acute myelogenous leukemia or chronic myelogenous leukemia in remission following HSCT exhibited significant numbers of peripheral blood CD8(+) T ...
2009 NOV 23 ... Current study results from the report, 'Overcoming resistance in chronic myelogenous leukemia,' have been published. "Chronic myeloid leukemia is defined by the acquired genetic ...
2009 SEP 28 ... in transgenic mice results in a myeloproliferative disorder that closely resembles human chronic myelogenous leukemia (CML). It has been reported that downregulation of JUNB expression is a universal ...
2009 OCT 12 ... (PI3K)/Akt pathway commonly occurs in cancers and is a crucial event in tumorigenesis. Chronic myelogenous leukemia (CML) is characterized by a reciprocal chromosomal translocation (9;22) that generates ...
2009 SEP 14 ... "Imatinib is used to treat chronic myelogenous leukemia (CML), but resistance develops in all phases of this disease. The purpose of the present ...
2009 SEP 28 ... A report, 'Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia,' is newly published data in Journal of Clinical Pharmacy & Therapeutics. ...
2009 NOV 9 ... Transplant Research (CIBMTR) data, we compared the transplant outcomes of patients with chronic myelogenous leukemia (CML) who were nonsmokers (NS) and past or current smokers (PCS). There were 2193 NS and ...
2009 OCT 12 ... (SFKs), which has demonstrated high efficiency in patients with imatinib-resistant chronic myelogenous leukemia. Here, we show that dasatinib weakly affects platelet activation by thrombin or ...
2009 OCT 19 ... inhibitors (HDACI) have been shown to enhance imatinib activity in imatinib-resistant chronic myelogenous leukemia. Against this background, we explored whether HDACI might provide an alternative ...
2009 NOV 2 ... research leading to the development of a therapy that now cures 95% of individuals with chronic myelogenous leukemia. D. Brian Spalding, FRS, FREng, Concentration, Heat & Momentum Limited ...
